Max Healthcare Institute shares experienced a notable decline in early trade on Friday, falling 2.47% to ₹988.30 as of 9:19 am, placing the stock among the top losers. The stock is currently a constituent of the NIFTY 50 index, making its performance closely watched by investors. This decline comes after the company's strong Q1 FY27 earnings announcement, which had previously driven shares up 1.4% to ₹1,021.60 on Thursday, August 13.
For the quarter-ending June 2026, Max Healthcare Institute delivered robust financial results with consolidated revenue of ₹2,366.17 crore, marking a healthy increase from ₹2,027.57 crore in the same period last year. The company's consolidated net profit for Q1 FY27 reached ₹322.96 crore, compared to ₹307.97 crore in Q1 FY26, demonstrating consistent profitability growth. Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) surged 15% to ₹704 crore from ₹613 crore in the corresponding quarter of the previous fiscal. However, margins contracted marginally to 24.8% from 24.9% in the year-ago period, indicating some pressure on operational efficiency despite strong top-line growth.
Annually, Max Healthcare Institute's consolidated revenue for the year-ending March 2026 surged to ₹8,373.45 crore, a significant 19.12% jump from ₹7,028.46 crore in the year-ending March 2025, according to Moneycontrol.com reports. Consolidated net profit also witnessed substantial growth, rising to ₹1,442.41 crore in March 2026 from ₹1,075.88 crore in March 2025, marking a 34.14% increase. EPS improved to ₹14.83 in March 2026 from ₹11.07 in the prior year. The company's Return on Equity (ROE) increased to 13.42% in March 2026 from 11.46% in the previous year, indicating improved operational efficiency. Book Value Per Share (BVPS) grew to ₹110.43 in March 2026 from ₹96.50 in March 2025, reflecting strong capital appreciation.
The company's board of directors has approved capital expenditure of ₹425 crore to set up an additional hospital block, demonstrating commitment to expansion despite current market challenges. Additionally, the board has given in-principle approval to set up medical colleges/medical institutions, indicating strategic diversification into education and research. This expansion strategy aligns with the company's growth objectives and positions it for long-term market expansion. The company's Debt to Equity ratio remained stable at 0.27 in March 2026, indicating a manageable debt structure that supports these expansion plans.
As reported by Moneycontrol.com, Max Healthcare Institute has announced several corporate actions including the grant of options under the Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 and an allotment of Equity Shares under the same scheme on August 13, 2026. The company recently announced a final dividend of ₹2.00 per share (20%) for the year-ending March 2026, with an effective date of July 03, 2026. This compares to a final dividend of ₹1.50 per share (15%) announced on May 20, 2025, with an effective date of July 04, 2025. Despite the recent price decline, the company's Total Assets increased to ₹17,230 crore in March 2026 from ₹15,214 crore in March 2025, while Reserves & Surplus grew to ₹9,773 crore from ₹8,408 crore, indicating strong balance sheet expansion.
